Supplement

Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya

E Wangeci Kagucia,¹ John N Gitonga,¹ Catherine Kalu,¹ Nickline Kuya,² Benard Ochieng,² Eric Ochomo,² Angela Karani,¹ James Nyagwange,¹ Boniface Karia,¹ Daisy Mugo,¹ Henry K Karanja,¹ James Tuju,¹ Agnes Mutiso,¹ Hosea Maroko,³ Lucy Okubi,³ Eric Maitha,⁴ Hossan Ajuck,⁴ Mary Bogita,⁴ Richmond Mudindi,⁴ David Mukabi,⁵ Wycliffe Moracha,⁵ David Bulimu,⁵ Nelson Andanje,⁵ Evans Shiraku,⁵ Rosemary Okuku,⁵ Monicah Ogutu,⁵ Rashid Aman,⁶ Mercy Mwangangi,⁶ Patrick Amoth,⁶ Kadondi Kasera,⁶ Wangari Ngʻangʻa,² Rodgers Mariga,⁵ Tobias Munabi,⁵ Susan M Ramadhan,⁵ Janet Mwikali,⁵ Rose Nasike,⁵ Cornelius Andera,⁵ Roselyne Nechesa,⁵ Benson K Kiplagat,⁵ Julius Omengo,⁵ Simon Oteba,⁵ Arthur Mwangi,⁴ Dorcas Mkanyi,⁴ George Karisa,⁴ Judith K Migosi,⁴ Patrick Msili,⁴ Samson Mwambire,⁴ Anthony M Boniface,⁴ Amek Nyaguara,¹ Shirine Voller,¹,8 Mark Otiende,¹ Christian Bottomley,8 Charles N Agoti,¹ Lynette I Ochola-Oyier,¹ Ifedayo M O Adetifa,¹,8 Anthony O Etyang,¹ Katherine E Gallagher,¹,8 Sophie Uyoga,¹ Edwine Barasa,¹ Philip Bejon,¹,9 Benjamin Tsofa,¹ Ambrose Agweyu,¹* George M Warimwe,¹,9* J Anthony G Scott¹,8,9*

¹KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

²KEMRI Center for Global Health Research (CGHR), Kisumu, Kenya

³KEMRI Center for Infectious and Parasitic Diseases Control Research, Alupe, Kenya

⁴Department of Health, Kilifi County, Kenya

⁵Department of Health, Busia County, Kenya

⁶Ministry of Health, Government of Kenya, Nairobi, Kenya

⁷Presidential Policy and Strategy Unit, The Presidency, Government of Kenya

⁸Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK

⁹Nuffield Department of Medicine, Oxford University, UK

^{*}These authors contributed equally to this work

Supplementary Table 1. Reported county of residence among Kenyan truckers

County	Frequency	Percent	County	Frequency	Percent
MOMBASA	156	23.4	KIRINYAGA	4	0.6
UASIN GISHU	76	11.4	LAIKIPIA	4	0.6
NAKURU	67	10.0	SIAYA	4	0.6
NAIROBI	60	9.0	KITUI	3	0.5
KIAMBU	41	6.1	MANDERA	3	0.5
BUSIA	40	6.0	EMBU	2	0.3
MACHAKOS	18	2.7	KAJIADO	2	0.3
KWALE	14	2.1	SAMBURU	2	0.3
BUNGOMA	13	2.0	GARISSA	1	0.2
KAKAMEGA	13	2.0	HOMABAY	1	0.2
KISUMU	13	2.0	KISII	1	0.2
KERICHO	8	1.2	MIGORI	1	0.2
MAKUENI	8	1.2	TAITA TAVETA	1	0.2
TRANS NZOIA	6	0.9	Uganda	1	0.2
MURANGA	5	0.8	Missing ^a	91	13.7
NYERI	5	0.8	Total	668	100
ELGEIYO MARAKWET	4	0.6			

^aCounty of residence not available for 90 of 101 truckers sampled at Magarini due to differences in the data collection form used; County of residence not collected for 1 trucker sampled at Malaba

Supplementary Table 2. Distribution of characteristics by site. Tests for heterogeneity conducted using analysis of variance (age) or chi-squared tests (all other variables)

Characteristic	Busia		Maga		Malaba		p-values	
	N= :	365	N= 1	L01	N= 3	364		
Mean age (SD), range ^a	41.0y (9.6)	20 – 68y	38.4y (9.3)	20 - 61y	42.3y (9.9)	19 – 78y	0.002	
Male, %	363	99.5%	100	99.0%	364	100%	0.249	
NAT positive, % ^b	15	4.3%	25	26.9%	18	5.2%	< 0.001	
Kenyan, %	294	80.5%	73	72.3%	301	82.7%	0.065	
Symptoms, %	0	0%	0	0%	0	0%	N/A	
Temperature ≥37.5°C°	0	0%	0	0%	1	0.3%	0.547	

Abbreviations: NAT, nucleic acid testing; OSBP, One Stop Border Post

^aMissingness: Magarini = 2; Malaba = 1

^bMissingness: Busia = 17; Magarini = 8; Malaba = 20

^cMissingness: Busia = 12; Magarini = 17; Malaba = 1

Supplementary Table 3. Stratum-specific tests for heterogeneity using crude anti-SARS-CoV-2 IgG seroprevalence

			% Crude anti-			
	N	Seropositive	SARS-CoV-2 IgG seroprevalence	95% CI	p-value	
Age ^a						
<30y	92	42	45.7	35.2 – 56.4	0.144ª	
30-39y	276	110	39.9	34.0 – 45.9		
40-49y	286	116	40.6	34.8 – 46.5		
50-59y	135	48	35.6	27.5 – 44.2		
>60y	38	13	34.2	19.6 – 51.4		
Sex						
Male	827	326	39.4	36.1 – 42.8	0.062 ^b	
Female	3	3	100.0	29.2 – 100.0		
NAT result						
Positive	58	32	55.2	41.5 – 68.3	0.007	
Negative	727	270	37.1	33.6 – 40.8		
Nationality						
Kenya	668	262	39.2	35.5 – 43.0	0.618	
Other	162	67	41.4	33.7 – 49.4		
Site						
Busia OSBP	365	163	44.7	39.5 – 49.9	0.009	
Magarini	101	43	42.6	32.8 – 52.8		
Malaba OSBP	364	123	33.8	28.9 - 38.9		

Abbreviations: NAT, nucleic acid test; OSBP, One Stop Border Post; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TDA, truck drivers and assistants

^aChi-square test for trend performed

^bFisher's exact test performed


Supplementary Figure 1. Map of Kenya showing the serosurvey sites




Supplementary Figure 2. Map showing the Northern Corridor road network which is used to transport freight from Mombasa, Kenya to other East African countries through Busia OSBP and Malaba OBSP, among other ports. Map from the Northern Corridor Transit and Transport Coordination Authority.¹



Supplementary Figure 3. Flow of TDA included in the SARS-CoV-2 serosurvey



Supplementary Figure 4. Sampling by date and site



V4



Test Justification Baseline

MINISTRY OF HEALTH Division of Disease Surveillance and Surveillance

	Division of	Distance Survey and Su
Case i	nvestigation for	m for 2019 Novel Coronavirus (COVID-19)
Date of reporting to r	national level: D[_][
		r investigation being conducted? □Presented at health facility □ Point of entry detection □Other
Date of investigation D[_](_]/M[_][_]		
Section 1: Patient is	nformation	
1.1 Unique Case Id	entifier (used in county):
1.2 Full name:	93. 831	NS-4
1.3 Nationality:		Contact Phone Number:
1.4 Citizenship: 1.5 Age: [_][_] in y 1.6 Sex: o Male of the color o	ears Female	Email address:
		Ward:
1.7.1 If health fac	ility, name of health fa	cility: Illage/estate):
section 2: Clinical in	formation	
□ Asymptomatic □ 2.2 Admission to hos	ymptoms: D [] [_]/ Unknown pital: of admission to hospit /Y[_][_][_][_]	
The state of the s	isolation = No = N	Yes □ Unknown

1

If yes, date of isolation: D [_		النال
2.2.4 Patient admitted to ICU 2.2.5 Was the patient ventilat 2.3 Health status at time of re	ed: = No = Yes = Un porting:	iknown
□ Stable □ Ser 2.3.1 Outcome □ Still in hos 2.3.2 Date of outcome (disch D [] []/M [] []/Y[arged, death) if applicabl	leath.
2.4 Patient symptoms (check	k all renorted symptoms)	ř
n History of fever / chills n General weakness n Cough n Sore throat n Runny nose n Other, specify	 Shortness of breath Diarrhea Nausea/vomiting Headache Irritability/Confusi 	De Pain (check all that apply) () Muscular () Chest () Abdominal () Joint on
Have the symptoms resolved	? Yes □ No □ Unknot	WIL 🗆
If Yes, Date of symptom reso	lution	Unknown 🗆
Patient signs: 2.5 Temperature0C		
2.6 Check all observed signs: Description Pharyngeal essudate Description Description Description	□ Coma □ Dyspnea / tac □ Abnormal lur	
n Other, specify:		XC. 597.
.7 Underlying conditions and • Pregnancy (trimester: • Cardiovascular disease, in • Diabetes • Liver disease • Chronic neurological or ne • Smoking (current or forms • Other, specify:	cluding hypertension euromuscular disease er smoker)	 □ Post-partum (< 6 weeks) □ Immunodeficiency, including HIV □ Renal disease □ Chronic lung disease □ Malignancy
Section 3: Exposure and trav asymptomatic)	rel information in the 1	4 days prior to symptom onset (prior to reporting if
3.1 Occupation: (tick any that a :: Student :: Working with animals 3.2 Has the patient travelled in If yes, please specify the pla	 Health care worker, (Health laboratory wo the 14 days prior to symp 	orker == Other, specify: ptom onset? == No == Yes == Unknown

	Country		City		Date	
1						
-	iont visited any	health care faci	litu(s) in the 14	days prior to sa	mintom oncer?	
=No	□ Yes		at y(s) in the 141	aays prior to sy	mpioni onset:	
3.4 Has the pat		ontact ¹ with a pe	rson with acute	respiratory infe	ection in the 14 days prior to	
□ No	o Yes	- Unknown				
If yes, co	otact setting (c	heck all that apply):			
	care setting opecify:	- Family setting	□ Workplace	□ Unknown		
			e or confirmed	case in the 14	days prior to symptom onset?	
□ No		= Unknown				
		case identifiers of	all probable or	confirmed case	151	
Case 1 id	entifier.	Case 2	identifier.	c	ase 3 identifier.	
If yes, cor	ntact setting (cl	eck all that apply):		A Paragraph and Ma	15.5
				= Unknown	Other, specify:	
		try for exposure:		ALFRADAMS AN	(1) jan 1900 (1900) (1900) Link	
Specimen colle		empleted by the he				
4.1 Was specin If no, why?		□ l=Yes	2=No			
		tion: D[_][_]/M				
4.3 Specimen t Other (specif	ype: NP Sw	ab 🗆 O	PSwab	Serum	☐ Sputum ☐ Tracheal As	pirate
4 4 Date specin	nen send to the	lab: D[][]/M	I 1/ 1/Y/ 1/	H H I		
(To be comple			الساء تسالسا			
	nen received in	the lab: D[_][_			1	
4.6 Name of co	nfirming lab: _				<u></u>	
4.7 Please spec	ify which assay	was used:		- 00		
4.8 Preliminary	lab results:					
4.9 Has sequen	cing been done	? = Yes = 1	√o ⊐ Unk	nown		
	laboratory con	firmation: D[_][The second secon	The second secon		

**Cook-contact* is defined as: 1. Health care associated exposure, including providing direct care for COVID-19 patients, working with health care workers infected with novel coronavirus, visiting patients or staying in the same close environment of a COVID-19 patient. 2. Working together in doze proximity or sharing the same closes environment with a with COVID-19 patient. 3. Traveling together with COVID-19 patient in any kind of conveyance. 4. Using in the same household as a COVID-19 patient.

Supplementary Form 2



Version 2.0

COVID – 19 Laboratory Request Form																		
Site	Name/F	acility			C	ontact I	Persor	1		Phone#			Date	of Dispa	tch			,
Email Address Count Date Sample Received					ounty	Sub-County									_			
Dat	e Sample	Receive	ed						Shipment T	emp. Max	t	Min			Ambier	nt		
Collected By:Date of Sample Collection																		
#	Case ID/	Type of Test Initial/ Repeat	Sample No	Full Name	ID PP No	Temp	Age	Sex M/F	Phone No.	Occupatio n	Nationalit Y	County Residenc e	Sub- County Of Residenc e	Village/ Estate	Contac t With case	Date Sympto m Onset	Symptom s (Cough, Fever, DIB etc)	Type of Sample(OP/NP/ Blood)
1																		
2																		
3																		
4																		
5																		
6																		
7																		
		·									·	·	·			·		

Page 1 of 1

References

1. Northern Corridor Transit and Transport Coordination Authority. *Northern Corridor Roads Network*. [cited 2020 December 17]; Available from: http://www.ttcanc.org/maps.php